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Pre-clinical studies of a novel anti-mitotic agent, amphethinile
A.T. McGown, C. Ewen, D.B. Smith & B.W. Fox
Paterson Institutefor Cancer Research, Christie Hospital and Holt Radium Institute, Manchester M20 9BX, UK.
Summary A new antitumour agent is described, which has been shown to induce a G2/M block in murine
leukaemia cells in vitro. In addition this agent has been shown to be equally toxic toward parental and
daunorubicin-resistant P388 cells in vitro. These resistant cells are highly cross-resistant to the established anti-
mitotic agents vincristine and vinblastine. Drug accumulation studies in cells have shown that whereas
resistance in this cell line is associated with decreased drug accumulation in the case of daunorubicin,
vincristine and vinblastine, this effect is much less pronounced for amphethinile.
It is proposed that amphethinile is a poor substrate for the drug efflux process associated with the
pleiotropic resistance mechanism operating in these cells. The data suggest that cell sensitivity towards
amphethinile differs qualitatively from that of the vinca alkaloids and anthracycline.
Pharmacokinetic studies in male mice were undertaken. Area under the curve values (AUC), show that
levels of 313 ig 1- 1 h- 1 were attained at doses equivalent to the LDI. The alpha half life is - 8min after a
bolus intravenous injection. The beta half life was 100min and relatively independent of dose level.
One of the most clinically useful groups of anticancer drugs
are the microtubule assembly inhibitors belonging to the
vinca alkaloid group. These drugs continue to be extracted
and purified from the Catharanthus species as it is still not
feasible to synthesise them by any commercially viable
procedure. A simple synthetic analogue may therefore
provide an alternative spindle poison, with sufficiently
different mode of action, cell permeability and other physico-
chemical characteristics to be a useful addition to the clinic.
An agent, (2-amino-3-cyano-5-(phenylthio)-indole, ICI
134154, Figure 1) has been identified which appears to affect
the microtubular control of mitosis. The compound, named
amphethinile, which is currently undergoing clinical trials,
has now been studied in more detail to determine if these
earlier observations can be substantiated and if so whether
the action of the drug closely resembles or differs
significantly from that of the vinca alkaloids. It would be
interesting to determine if this synthetic compound shows
cross resistance to a cell line which exhibits pleiotropic drug
response characteristics of some naturally occurring
antitumour agents, including the vinca alkaloids (Blick et al.,
1986; Dano et al., 1983; Gerlach et al., 1986).
In addition, following perclinical formulation and
toxicology, the pharmacokinetic characteristics of this agent
have been determined in male mice in preparation for the
clinical studies which will be described elsewhere.
Materials and methods
Drugs
Amphethinile was kindly donated by ICI (Alderley Park,
Cheshire, UK). The compound is a pale yellow granular
solid, m.p. 190.5-191°C. It is readily soluble in acetone,
dimethyl sulphoxide and acetonitrile, but sparingly soluble in
toluene. The initial product is >99% pure by spectral,
HPLC and TLC analytical methods.
Daunorubicin was obtained from May and Baker
(Dagenham, UK) and the vinca alkaloids from Amersham
International plc (Amersham, Bucks, UK).
Cell culture
A cell line showing decreased sensitivity to daunorubicin
(P388 R8/13) was developed from the parental (P388) cell
line by incremental challenge with the drug in vitro as
previously described (McGown et al., 1983). Both cell lines
are grown in RPMI medium supplemented with 10% horse
serum (Gibco, UK). Cells are regularly screened and shown
to be mycoplasma free. Growth inhibition studies were
carried out by back extrapolation of growth curves following
a h challenge with drug. Cell counts were performed in
triplicate on an electronic cell counter (Coulter Electronics,
Luton, UK).
Measurement ofdrug accumulations in cells
Cells, in exponential growth, were centrifuged (800g, 5min,
4°C) and resuspended at a cell concentration of 2 x 105 ml-1.
Drug incubations were performed as described below.
Daunorubicin and amphethinile were employed at doses
which produced comparable survival data in the resistant cell
line. These doses are necessarily high in order to provide for
the spectral sensitivity used. Even at this high level however
(20 x ID50), the differential accumulation of daunorubicin,
characteristic of the pleiotropic drug response to the drug,
was evident. The use of the lower levels of radiolabelled
vincristine was used to confirm the differential uptake
characteristic of the pleiotropic drug resistance. Cell lysis was
performed by sonication (MSE 20gm peak to peak, 20sec).
All experiments were performed in triplicate.
Daunorubicin Cells were resuspended in serum-free medium
(RPMI) and incubated with daunorubicin (1OgM, 37°C, 2h).
The cells were pelleted by centrifugation (160g, 10min, 4C),
washed in cold PBS and lysed in distilled water. Dauno-
rubicin was extracted 4 x 3 mls of CHCI3: isoamyl alcohol
(24:1) and the concentration determined fluorimetrically
(Rex
=480 nm, Aem = 570nm).
Vinca alkaloids Cells were incubated with either 3H-
vincristine (4.6Cimmol-1, 25 nm, 1 h, 37°C) or 3H-
vinblastine (9.9 Cimmol 1, 25 nm, h, 37°C) in serum free
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Figure 1 Structure of Amphethinile, (ICI 134, 154).
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medium, pelleted by centrifugation, washed twice in ice cold
PBS, lysed and counted using Aquasol (New England
Nuclear).
Amphethinile Amphethinile was dissolved in methanol
(10mM stock solution) immediately before addition to the
cells. The volume of methanol in the final incubation
mixture was < 1%, which does not modify the uptake of any
of the drugs used in either drug sensitive or resistant lines. In
addition, the same level of methanol was used in the control
cultures. Drug incubations (1OgM, 2h, 37°C) were performed
in RPMI medium in the presence or absence of horse serum
(10%). Cell suspensions (100ml) were centrifuged (800g,
10min, 4C), washed in PBS, lysed in distilled water by
sonication, and the drug extracted into CHC13. The
amphethinile concentration was determined spectrophoto-
metrically (i=304nm) relative to a standard curve.
Flow cytometry
L1210 cells (ID50 amphethinile=2.8urm) at -105ml- 1 in
exponential growth were treated for 20h with amphethinile
at the concentrations stated. The cells were pelleted by
centrifugation, washed, fixed in acetone-ethanol, treated with
RNAase and the DNA stained with Propidium iodide as
described previously (McGown et al., 1984). DNA
histograms were obtained from - 5 x 104 cells.
Animal toxicity
Initial toxicity studies on this agent were performed under
contract in MFI-strain male mice following an acute i.v. and
i.p. administration as well as a 4-weekly 5 day sub acute
study. For the subsequent pharmacokinetic studies,
additional toxicity data were obtained in our laboratory
strain of mice (BDFI). However the two strains showed very
similar sensitivity to the formulated agent.
Pharmacokinetic studies
For these studies 8-10 week old Paterson BDF1 male mice
were used. In these mice the LD10 was -400mgm-2 by i.v.
administration. Doses administered were 100, 200 and
400mgm 2. At 5, 15, 30, 60min, 2, 4, 6 and 8h after
injection, three mice per time point were anaesthetised by
fluothane (ICI) inhalation and exsanguinated from a small
incision in the lateral canthus. Following collection, the
blood was allowed to clot and the serum removed. Drug was
extracted with chloroform, vacuum-evaporated and
redissolved in methanol. Serum levels of the drug and any
metabolites present were determined by reverse phase HPLC
(5u ODS) using 70% methanol and 30% water containing
0.1% phosphoric acid as the mobile phase. The lower limit
of detection was 0.1/.tgml-1. Data were fitted using least
squares regression analysis.
Results
In vitro studies
From the growth inhibition data (Table I) it can be seen that
the primary resistance to daunorubicin (34-fold) is
accompanied by considerable cross resistance to the vinca
alkaloids vinblastine and vincristine (28- & 16-fold
respectively). However no cross resistance is observed for
amphethinile. This would indicate that the method of cell
killing by this agent is qualitatively different from that
produced by the vinca alkaloids, since the difference
expected if a pleiotropic resistance mechanism was involved
was not observed. Drug accumulation measurements (Table
II) show reduced drug accumulation in the resistant cell line.
However the ratio of drug accumulated in the parental cell
line compared to the resistant is greater for daunorubicin
(2.72-fold), vinblastine (3.72-fold) and vincristine (2.25-fold)
Table I Growth inhibition of parental (P388) and daunorubicin
resistant P388 R8/13 cell lines. The difference in sensitivity is
indicated in parentheses
ID50(M X 10 9)
Cell line Daunorubicin Vinblastine Vincristine Amphethinile
P388 19 1.7 2.2 480
P388 R8/13 650( x 34) 47( x 28) 35( x 16) 480( x 1)
Table II Drug accumulation (mol 10-6 cells) in parental (P388) and
daunorubicin resistant (P388 r8/13) cells. (* denotes drug incubation
in the presence of serum). Figures in parentheses indicate standard
deviation
Daunorubicin Vinblastine Vincristine Amphethinile
Cell line (M X 10 9) (M X J 12) (MX 10 2) (MX 10 9)
P388 4.08(0.86) 1.21(0.01) 0.90(0.01) 96.6 (0.1)
2.30(0.02)*
P388 R8/13 1.50(0.30) 0.37(0.08) 0.40(0.01) 66.0 (0.10)
1.50(0.02)*
than for amphethinile (1.5-fold). The presence of serum
reduces cellular accumulation of amphethinile by some 40-
fold. However, the differential accumulation observed
between the parental and resistant cell lines is maintained
(- 1.5-fold).
From the flow cytometric analysis (Figure 2), amphethinile
can be seen to cause a G2/M phase arrest in cell cycle
progression. This is similar to that observed for the vinca
alkaloids (McGown et al., 1984).
Animal toxicity
Preclinical toxicology was undertaken using the clinically
formulated drug. The formulation consisted of 10g
amphethinile and 100g Solutol HS15 diluted to 200ml with
70% ethanolic citrate buffer at pH 6.0. The resulting drug
concentration was 50mgml-1. The highest level of Solutol
alone, 18mg/mouse, was shown to be non-toxic under these
administration conditions.
The LD10 values were 137mgkg-1 (411mgm-2, i.v.),
152mgkg-1 (456mgm 2, i.p.) and - 50mgkg 1
(150mgm2, i.p.) daily for 5 days, four successive weekly
administrations. Germ cell necrosis was seen in most mice, a
minimal necrosis was seen in glandular, squamous or sub-
mucosal areas of the stomach and of the crypt epithelium
cells in the small intestine. However these latter changes were
only seen after the highest dose levels. In a similar way,
some bone marrow lesions were seen in the highest, near
lethal doses only.
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Figure 2 DNA distributions from L1210 cells treated with
amphethinile at (a) 0gM (control); (b) 1 pM; (c) 2,UM and (d)
4pM for 20h at 37°C. All the histograms are from -5 x 104
cells.
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Pharmacokinetics
The pharmacokinetics data for this agent in the mouse are
summarised in Tables III and IV. At this stage, the total
level of the drug (>90%) was measured, i.e., chloroform
extractable, in order to compare directly with the clinical
data to follow. At this stage it is not possible to indicate
whether the slow release of drug from the protein-bound
complex may or may not contribute to the effectiveness of
the drug in vivo. This must be the subject of a separate
investigation.
The drug showed a biphasic decline in serum
concentration, the half life (beta phase) remaining constant
with increasing dose. Doubling of the dose resulted in a
three fold increase in the area under the curve (AUC). The
AUC value at the LD10 value was 313,ugl-1 h-1.
Table III Time course of amphethinile in serum. Concentration of
amphethinile in mouse serum (pgml-1) at different times after
treatment
Time (min)
Dose
(mgm-2) 5 15 30 60 120 240 360 480
100 26.5 16.8 11.4 7.11 4.70 2.97 1.04 -
200 85.7 57.2 - 25.9 14.7 4.5 3.4 0.83
400 193 138 122 89 57 17 9.9 6
Table IV Pharmacokinetic parameters in mice. The initial (a) and
final (/B) half-lives of amphethinile in mouse serum following
different treatment levels
Dose (mgm2) T2a(min) TIfl(min) AUC (pggl' 1h)
100 9.62+ 1.05 124 + 18.6 34.5
200 8.53+0.93 79.6+ 7.9 95.4
400 2.13+1.85 80.6+ 5 313
Discussion
This work describes the effect of the novel anti-microtubule
agent amphethinile on parental and daunorubicin resistant
P388 cells in vitro. We have shown that there is a lack of
cross-resistance towards amphethinile in this daunorubicin
resistant cell line. This is in contrast to the vinca alkaloids.
Cross resistance between the anthracycline antibiotics and
the vinca alkaloids has been described in many cells types
(Dano et al., 1983; Tsuruo, 1983; Stark, 1986). This multi-
drug or pleiotropic drug resistance exhibited by these cell
lines, has been shown to be associated with decreased
cellular drug retention. The precise mechanism by which this
occurs is not known but is a protein mediated (Blick et al.,
1986; Gerlach et al., 1985; Stark, 1986), energy dependent
process (Dano et al., 1983). It is likely that the anthra-
cyclines and vinca alkaloids share a common or related
efflux pathway. The lack of cross-resistance observed
towards amphethinile, together with the decreased drug
accumulation differential of 33% observed between the
parental and resistant cell lines is evidence that amphethinile
is either not a substrate or is a poor substrate for this drug
efflux process. This difference between the vinca alkaloids
and amphethinile may prove useful in the treatment of
tumours which have developed resistance to vinca alkaloids.
In view of the clinical potential of this agent, it was
submitted to preclinical formulation and toxicological
studies. It was shown to be 100-fold less toxic than
vincristine. Pharmacokinetic studies further indicated that
there was a beta half-life of - 100min in mice, which was
independent of dose administered, which suggests that there
is no saturable metabolic process involved. In view of the
current interest in comparing AUC measurements, (Collins
et al., 1986), the value observed in serum following i.v. bolus
administration, indicated that - 313Mg 1 - I h- I was obtained
at the LD10 levels. This may be a useful indicator for
appropriate dose escalation in phase I trials of this agent.
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